Skip to main content

Table 2 Ongoing clinical trials evaluating checkpoint inhibitor plus VEGF TKI in unresectable gastroesophageal cancer

From: The integration of immune checkpoint inhibitors with VEGF targeted agents in advanced gastric and gastroesophageal adenocarcinoma: a review on the rationale and results of early phase trials

NCT number Status Interventions Phases Treatment setting Results
NCT02999295 Completed Nivolumab + ramucirumab Phase 1/2 2nd line ORR: 26.7%
DCR: 62.2%
Grade 3–4 AE: 33/46
No deaths
NCT03406871 Active, not recruiting Nivolumab + regorafenib Phase 1 3rd line ORR: 44%
mPFS: 5.6 mo
mOS: 12.3 mo
Grade 3–4 AEs: 20/50
3 DLTs with Rego 160 mg
NCT02572687 Active, not recruiting Durvalumab + ramucirumab Phase 1 2nd line ORR: 21%
mOS: 2.6 mo
mPFS: 12.4 mo
Grade 3–4 AE: 37.9%
NCT02443324 Active, not recruiting Pembrolizumab + ramucirumab Phase 1 4th line ORR: 7%
DCR: 44%
Grade 3–4 AE: 11/29
NCT03609359 Active, not recruiting Pembrolizumab + lenvatinib Phase 2 1st of 2nd line ORR: 69%
DCR: 100%
mPFS: 6.9 mo
Grade 3–4 AE: 14/29
No Gr 4–5 AE
NCT02942329 Unknown SHR1210 + apatinib Phase ½ 2nd line ORR: 16%
DCR: 78%
Grade 3–4 AE: 20/33*
4/43 DLTs
NCT03539822 Recruiting Cabozantinib + durvalumab Phase 1/2 3rd line ORR: 25%
DCR: 85%
Median time to progression: 16 weeks
No DLTs
NCT04267549 Recruiting Sintilimab + apatinib + chemotherapy Phase 2 2nd line Not yet reported
NCT04182724 Recruiting Camrelizumab + apatinib + nab-paclitaxel Phase 1/2 2nd line Not yet reported
NCT04006821 Recruiting Camrelizumab + apatinib Phase 2 2nd line Not yet reported
NCT03995017 Recruiting Rucaparib + ramucirumab + nivolumab Phase 1/2 2nd line Not yet reported
NCT03966118 Recruiting Avelumab + ramucirumab + paclitaxel Phase 2 2nd line Not yet reported
NCT03813784 Recruiting SHR-1210 + capecitabine + oxaliplatin then shr-1210 + apatinib versus capecitabine + oxaliplatin Phase 3 1st line Not yet reported
NCT03797326 Recruiting Pembrolizumab + lenvatinib Phase 2 3rd line Not yet reported
NCT03603756 Recruiting SHR-1210 + apatinib + chemotherapy Phase 2 1st line Not yet reported
NCT03475953 Recruiting Regorafenib + avelumab Phase 1/2 2nd line Not yet reported
NCT03321630 Recruiting Lenvatinib + pembrolizumab Phase 2 2nd line Not yet reported
NCT03170960 Recruiting Cabozantinib + atezolizumab Phase 1/2 2nd line Not yet reported
NCT02734004 Active, not recruiting MEDI4736 + olaparib ± bevacizumab Phase 1/2 2nd line Not yet reported
  1. *Toxicity results of overall population including patients with hepatocellular cancer patients. Grade 3–4 AEs represent incidence of patients receiving recommended phase II trial dose